PDL BioPharma Company Profile (NASDAQ:PDLI)

About PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Symbol: NASDAQ:PDLI
CUSIP: 69329Y10
Web: www.pdl.com

Capitalization:

Market Cap: $384.75 million
Outstanding Shares: 160,984,000

Average Prices:

50 Day Moving Avg: $2.22
200 Day Moving Avg: $2.29
52 Week Range: $1.93 - $3.77

P/E:

Trailing P/E Ratio: 26.26
Foreward P/E Ratio: 14.06
P/E Growth: 0.64

Sales & Book Value:

Annual Revenue: $103.28 million
Price / Sales: 3.73
Book Value: $4.65 per share
Price / Book: 0.51

Profitability:

EBIDTA: $45.51 million
Net Margins: 49.04%
Return on Equity: 29.87%
Return on Assets: 20.18%

Debt:

Debt-to-Equity Ratio: 0.31%
Current Ratio: 2.92%
Quick Ratio: 2.91%

Misc:

Average Volume: 1.89 million shs.
Beta: 0.52
Short Ratio: 7.28

Frequently Asked Questions for PDL BioPharma (NASDAQ:PDLI)

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its board has approved a share buyback plan on Saturday, April 8th 2017, which allows the company to repurchase $30,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 8.6% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) released its earnings results on Wednesday, May, 3rd. The company reported $0.08 EPS for the quarter, topping the Zacks' consensus estimate of $0.05 by $0.03. The company had revenue of $45.44 million for the quarter. PDL BioPharma had a net margin of 49.04% and a return on equity of 29.87%. View PDL BioPharma's Earnings History.

When will PDL BioPharma make its next earnings announcement?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for PDL BioPharma.

Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?

2 analysts have issued 12 month price targets for PDL BioPharma's shares. Their forecasts range from $3.50 to $4.00. On average, they expect PDL BioPharma's share price to reach $3.75 in the next twelve months. View Analyst Ratings for PDL BioPharma.

What are analysts saying about PDL BioPharma stock?

Here are some recent quotes from research analysts about PDL BioPharma stock:

1. According to Zacks Investment Research, "PDL BioPharma reported better than expected earnings in the first quarter of 2017 whereas revenue significantly decreased year over year. The company is focused on acquiring and managing income-generating assets. PDL BioPharma has royalty agreements with several companies, whereby it has royalty rights on product sales. We are positive on the company’s recent strategic shift, whereby it is making equity investments in product-focused companies. However, the company’s dependence on revenues from royalties is not a risk-free strategy. Moreover, the company’s top line declined materially after it stopped receiving payments from certain Queen et al. patent license. The decrease in royalties from PDL's Queen et al. patents is due to the expiration of the patent license agreement with Genentech. PDL BioPharma’s shares have underperformed the Medical-Biomedical/Genetics industry in the past one year." (5/15/2017)
2. Cowen and Company analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)

Who are some of PDL BioPharma's key competitors?

Some companies that are related to PDL BioPharma include TG Therapeutics (TGTX), Esperion Therapeutics (ESPR), Aduro BioTech (ADRO), Keryx Biopharmaceuticals (KERX), Omeros (OMER), Anika Therapeutics (ANIK), Acorda Therapeutics (ACOR), Revance Therapeutics (RVNC), Aclaris Therapeutics (ACRS), La Jolla Pharmaceutical Company (LJPC), MacroGenics (MGNX), Cytokinetics (CYTK), Vanda Pharmaceuticals (VNDA), Inovio Pharmaceuticals (INO), Achillion Pharmaceuticals (ACHN), Enanta Pharmaceuticals (ENTA), Calithera Biosciences (CALA) and Neuroderm Ltd (NDRM).

Who owns PDL BioPharma stock?

PDL BioPharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.57%), Renaissance Technologies LLC (7.27%), Dimensional Fund Advisors LP (3.43%), Acadian Asset Management LLC (2.91%), Mackenzie Financial Corp (2.91%) and AQR Capital Management LLC (2.82%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke. View Institutional Ownership Trends for PDL BioPharma.

Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?

PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., Acadian Asset Management LLC, American International Group Inc., Geode Capital Management LLC, Legal & General Group Plc and ClariVest Asset Management LLC. View Insider Buying and Selling for PDL BioPharma.

Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?

PDL BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Seizert Capital Partners LLC, Thrivent Financial For Lutherans, Vanguard Group Inc., AQR Capital Management LLC, Nomura Holdings Inc., UBS Group AG and Bank of Montreal Can. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke. View Insider Buying and Selling for PDL BioPharma.

How do I buy PDL BioPharma stock?

Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of PDL BioPharma stock cost?

One share of PDL BioPharma stock can currently be purchased for approximately $2.39.

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (?)

Ratings Breakdown:	1 Hold Rating, 1 Buy Rating
Consensus Rating:	Buy (Score: 2.50)
Consensus Price Target:	$3.75 (56.90% upside)

Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
5/3/2017	Cowen and Company	Reiterated Rating	Hold		High
12/22/2016	Piper Jaffray Companies	Initiated Coverage	Overweight	$4.00	N/A
2/23/2016	Royal Bank of Canada	Lower Price Target	Sector Perform	$5.00 -> $4.00	N/A

(Data available from 5/27/2015 forward)

Earnings History for PDL BioPharma (NASDAQ:PDLI)

Earnings by Quarter for PDL BioPharma (NASDAQ:PDLI)

Earnings History by Quarter for PDL BioPharma (NASDAQ:PDLI)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/2/2017
5/3/2017	Q1 2017	$0.05	$0.08		$45.44 million	View	Listen
11/3/2016	Q316	$0.08	$0.08	$50.69 million	$53.60 million	View	N/A
8/4/2016	Q216	$0.08	$0.09	$33.46 million	$21.00 million	View	N/A
5/4/2016	Q116	$0.50	$0.52	$142.05 million	$103.10 million	View	N/A
2/22/2016	Q415	$0.54	$0.61	$149.20 million	$178.10 million	View	Listen
11/4/2015	Q315	$0.61	$0.42	$164.80 million	$124.60 million	View	N/A
8/5/2015	Q215	$0.52	$0.47	$137.75 million	$138.10 million	View	N/A
5/6/2015	Q115	$0.52	$0.50	$140.80 million	$149.71 million	View	N/A
2/23/2015	Q414	$0.57	$0.32	$158.15 million	$117.10 million	View	Listen
11/10/2014	Q314	$0.56	$0.61	$165.10 million	$164.60 million	View	N/A
8/18/2014	Q214	$0.46	$0.52	$134.07 million	$162.80 million	View	Listen
5/12/2014	Q114	$0.45	$0.44	$130.93 million	$139.70 million	View	N/A
3/3/2014	Q413	$0.43	$0.39	$115.22 million	$110.10 million	View	N/A
11/6/2013	Q313	$0.37	$0.36	$97.09 million	$97.30 million	View	N/A
8/8/2013	Q2 2013	$0.54	$0.62	$138.20 million	$143.60 million	View	N/A
5/9/2013	Q1 2013	$0.35	$0.36	$91.69 million	$91.80 million	View	N/A
3/1/2013	Q4 2012	$0.31	$0.34	$86.08 million	$86.10 million	View	N/A
11/5/2012	Q312	$0.33	$0.32	$85.03 million	$85.20 million	View	N/A
8/2/2012		$0.44	$0.52			View	N/A
5/3/2012		$0.27	$0.29			View	N/A
2/23/2012		$0.28	$0.24			View	N/A
11/9/2011		$0.27	$0.28			View	N/A
7/27/2011		$0.39	$0.39			View	N/A
4/27/2011		$0.24	$0.25			View	N/A
2/28/2011		$0.21	$0.20			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)

Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.17 EPS

Current Dividend Information for PDL BioPharma (NASDAQ:PDLI)

Most Recent Dividend:	6/13/2016
Annual Dividend:	$0.10
Dividend Yield:	4.18%
Payout Ratio:	9.43% (Trailing 12 Months of Earnings) 38.46% (Based on This Year's Estimates) 58.82% (Based on Next Year's Estimates)

Dividend Payments by Quarter for PDL BioPharma (NASDAQ:PDLI)

Dividend History by Quarter for PDL BioPharma (NASDAQ:PDLI)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/4/2016	quarterly	$0.05	6.25%	6/2/2016	6/6/2016	6/13/2016
2/1/2016	quarterly	$0.05	7.27%	3/2/2016	3/4/2016	3/11/2016
2/2/2015	quarterly	$0.15	8.22%	6/1/2016	6/5/2016	6/12/2016
1/30/2015	quarterly	$0.15	8.23%	6/3/2015	6/5/2015	6/12/2015
1/30/2015	quarterly	$0.15	8.23%	3/3/2015	3/5/2015	3/12/2015
1/30/2015	quarterly	$0.15	8.23%	12/2/2015	12/4/2015	12/11/2015
1/30/2015	quarterly	$0.15	8.23%	9/2/2015	9/4/2015	9/11/2015
1/31/2014	quarterly	$0.15	6.59%	9/3/2014	9/5/2014	9/12/2014
1/31/2014	quarterly	$0.15	6.59%	3/3/2014	3/5/2014	3/12/2014
1/31/2014	quarterly	$0.15	6.59%	12/3/2014	12/5/2014	12/12/2014
1/31/2014	quarterly	$0.15	6.59%	6/3/2014	6/5/2014	6/12/2014
1/31/2013	quarterly	$0.15	8.72%	12/3/2013	12/5/2013	12/12/2013
1/31/2013	quarterly	$0.15	8.72%	6/3/2013	6/5/2013	6/12/2013
1/31/2013	quarterly	$0.15	8.72%	9/3/2013	9/5/2013	9/12/2013
1/30/2013	quarterly	$0.15	8.72%	3/1/2013	3/5/2013	3/12/2013

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for PDL BioPharma (NASDAQ:PDLI)

Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 78.88%

Institutional Ownership by Quarter for PDL BioPharma (NASDAQ:PDLI)

Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/24/2017	Peter S Garcia	VP	Buy	25,000	$1.98	$49,500.00
8/9/2016	Peter S Garcia	VP	Buy	10,000	$3.00	$30,000.00
12/15/2015	Peter S. Garcia	CFO	Buy	5,000	$3.64	$18,200.00
12/14/2015	Peter S. Garcia	CFO	Buy	10,000	$3.42	$34,200.00
12/7/2015	Steffen Pietzke	CAO	Buy	20,590	$3.64	$74,947.60
8/14/2015	Peter S Garcia	CFO	Buy	20,000	$5.83	$116,600.00
11/26/2014	Harold E Selick	Director	Buy	6,000	$8.08	$48,480.00

(Data available from 1/1/2013 forward)

Headline Trends for PDL BioPharma (NASDAQ:PDLI) Latest Headlines for PDL BioPharma (NASDAQ:PDLI)

Source:

Date	Headline
	PDL BioPharma: Now Is The Time To Buy - Seeking Alpha seekingalpha.com - May 19 at 11:57 AM
	Brokerages Expect PDL BioPharma Inc (PDLI) to Announce $0.04 EPS www.americanbankingnews.com - May 16 at 10:46 AM
	PDL BioPharma Inc (PDLI) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - May 15 at 12:22 PM
	LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR finance.yahoo.com - May 11 at 8:32 AM
	PDL BioPharma Inc (PDLI) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS www.americanbankingnews.com - May 6 at 1:00 AM
	LENSAR Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam Tomographers (PDLI) www.streetinsider.com - May 5 at 7:26 PM
	LENSAR® Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam® Tomographers finance.yahoo.com - May 5 at 7:26 PM
	PDL BioPharma Inc (PDLI) Issues Quarterly Earnings Results www.americanbankingnews.com - May 5 at 2:30 PM
	Edited Transcript of PDLI earnings conference call or presentation 3-May-17 8:30pm GMT finance.yahoo.com - May 4 at 8:06 AM
	PDL BioPharma's (PDLI) "Hold" Rating Reiterated at Cowen and Company www.americanbankingnews.com - May 4 at 12:06 AM
	Cowen and Company Reiterates "Hold" Rating for PDL BioPharma Inc (PDLI) www.americanbankingnews.com - May 4 at 12:00 AM
	EARNINGS SUMMARY: Details of PDL BioPharma Inc. Q1 Earnings Report www.rttnews.com - May 3 at 7:53 PM
	Investor Network: PDL BioPharma, Inc. to Host Earnings Call finance.yahoo.com - May 3 at 7:53 PM
	PDL BioPharma Announces First Quarter 2017 Financial Results finance.yahoo.com - May 3 at 7:53 PM
	PDL BioPharma posts 1Q profit finance.yahoo.com - May 3 at 7:53 PM
	PDL BioPharma (PDLI) Receives Media Impact Rating of 0.69 www.americanbankingnews.com - May 2 at 2:50 PM
	PDL BioPharma (PDLI) Earning Somewhat Positive Media Coverage, Study Shows www.americanbankingnews.com - April 28 at 1:01 AM
	PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017 finance.yahoo.com - April 26 at 6:05 PM
	PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : April 26, 2017 finance.yahoo.com - April 26 at 6:05 PM
	PDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : April 25, 2017 finance.yahoo.com - April 25 at 10:21 AM
	ETFs with exposure to PDL BioPharma, Inc. : April 24, 2017 finance.yahoo.com - April 24 at 5:52 PM
	PDL BioPharma (PDLI) Receives Coverage Optimism Rating of 0.44 www.americanbankingnews.com - April 24 at 3:22 PM
	PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck finance.yahoo.com - April 24 at 12:29 PM
	PDL BioPharma to be paid $19.5 million by Merck to settle Keytruda patent suit finance.yahoo.com - April 24 at 12:29 PM
	PDL BioPharma (PDLI) Earning Somewhat Critical News Coverage, Study Shows www.americanbankingnews.com - April 21 at 9:21 PM
	PDL BioPharma (PDLI) Board of Directors Announces Stock Repurchase Plan www.americanbankingnews.com - April 8 at 8:34 AM
	PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017 finance.yahoo.com - April 7 at 11:49 AM
	TheStreet Downgrades PDL BioPharma Inc (PDLI) to D+ www.americanbankingnews.com - April 5 at 3:16 PM
	PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue? finance.yahoo.com - April 3 at 9:24 AM
	Insider Buying: PDL BioPharma Inc (PDLI) VP Acquires 25,000 Shares of Stock www.americanbankingnews.com - March 27 at 11:04 PM
	PDL BioPharma (PDLI) Presents At Oppenheimer 27th Annual Healthcare Conference seekingalpha.com - March 21 at 6:58 PM
	Zacks: PDL BioPharma Inc (PDLI) Given Average Rating of "" by Brokerages www.americanbankingnews.com - March 21 at 10:52 AM
	PDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference finance.yahoo.com - March 14 at 10:19 AM
	PDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers biz.yahoo.com - March 10 at 9:05 AM
	PDL BioPharma (PDLI) Presents At Cowen and Company 37th Annual Health Care Conference seekingalpha.com - March 8 at 3:52 PM
	PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits biz.yahoo.com - March 8 at 9:10 AM
	PDL BIOPHARMA, INC. Financials finance.yahoo.com - March 7 at 7:00 PM
	PDL BioPharma to Present at Two Upcoming Investor Conferences - PR Newswire (press release) www.prnewswire.com - March 4 at 7:12 PM
	PDL BioPharma: 2017 Could Be A Game-Changer - Seeking Alpha seekingalpha.com - March 4 at 7:12 PM
	EARNINGS SUMMARY: Details of PDL BioPharma Inc. Q4 Earnings Report www.rttnews.com - March 3 at 7:11 PM
	Why Tenet Healthcare, Scientific Games, and PDL BioPharma Jumped Today www.fool.com - March 3 at 7:10 PM
	Edited Transcript of PDLI earnings conference call or presentation 1-Mar-17 9:30pm GMT finance.yahoo.com - March 2 at 8:44 AM
	PDL BioPharma to Present at Two Upcoming Investor Conferences finance.yahoo.com - March 2 at 8:44 AM
	PDL BioPharma Board Authorizes $30 Mln Stock Buyback - Quick Facts www.rttnews.com - March 1 at 7:23 PM
	PDL BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fina us.rd.yahoo.com - March 1 at 7:23 PM
	6:35 am PDL BioPharma Board authorizes the repurchase of up to $30 mln of the company's common stock through March 2018 finance.yahoo.com - March 1 at 10:31 AM
	PDL BioPharma Announces $30 Million Share Repurchase Program finance.yahoo.com - March 1 at 10:31 AM
	Q4 2016 PDL BioPharma Inc Earnings Release - After Market Close biz.yahoo.com - March 1 at 10:31 AM
	Better Buy: PDL BioPharma, Inc. vs. Johnson & Johnson www.fool.com - February 27 at 9:54 AM
	PDL BioPharma to Announce Fourth Quarter / Year-End 2016 Financial Results on March 1, 2017 finance.yahoo.com - February 22 at 9:14 AM